|
1
|
Kraus S, Nabiochtchikov I, Shapira S and
Arber N: Recent advances in personalized colorectal cancer
research. Cancer Lett. 347:15–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O Connell JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new American Joint Committee on
Cancer 6th edition staging. J Natl Cancer Inst. 96:1420–1425. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mather C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagtegaal ID, Quirke P and Schmoll HJ: Has
the new TNM classification for colorectal cancer improved care? Nat
Rev Clin Oncol. 9:119–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watanabe T: Biomarker for high-risk
patients with stage II colon cancer. Lancet Oncol. 14:1247–1248.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chua YJ and Zalcberg JR: Progress and
challenges in the adjuvant treatment of stage II and III colon
cancers. Expert Rev Anticancer Ther. 8:595–604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grady WM and Pritchard CC: Molecular
alterations and biomarkers in colorectal cancer. Toxicol Pathol.
42:124–139. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ye JJ and Cao J: MicroRNAs in colorectal
cancer as markers and targets: Recent advances. World J
Gastroenterol. 20:4288–4299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma J, Dong C and Ji C: MicroRNA and drug
resistance. Cancer Gene Ther. 17:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oqin S, Chan AT, Fuchs CS and Giovannucci
E: Molecular pathological epidemiology of colorectal neoplasia: An
emerging transdisciplinary and interdisciplinary field. Gut.
60:397–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okugawa Y, Grady WM and Goel A: Epigenetic
alterations in colorectal cancer: Emerging biomarkers.
Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo Y, Tsuchiya KD, ll Park D, Fausel R,
Kanngurn S, Welcsh P, Dzieciatkowski S, Wang J and Grady WM: RET is
a potential tumor suppressor gene in colorectal cancer. Oncogene.
32:2037–2047. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hernando E: microRNAs and cancer: Role in
tumorigenesis, patient classification and therapy. Clin Transl
Oncol. 9:155–160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kosaka N, Iguchi H, Yoshioka Y, Takeshita
F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular
transfer of microRNAs in living cells. J Boil Chem.
285:17442–17452. 2010. View Article : Google Scholar
|
|
16
|
Zhou JJ, Zheng S, Sun LF and Zheng L:
MicroRNA regulation network in colorectal cancer metastasis. World
J Biol Chem. 5:301–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vilarr E, Tabernero J and Gruber SB:
Micromanaging the classification of colon cancer: The role of the
microRNAome. Clin Cancer Res. 17:7207–7209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cummins JM, He Y, Leary RJ, Paqliarini R,
Diaz LA Jr, Sjiblom T, Barad O, Bentwich Z, Szafranska AE,
Labourier E, et al: The colorectal microRNAome. Proc Natl Acad Sci
USA. 103:3687–3692. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hollis M, Nair K, Vyas A, Chaturvedi LS,
Gambhir S and Vyas D: MicroRNAs protential utility in colon cancer:
Early detection, prognosis and chemosensitivity. World J
Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Di Leva G, Cheung DG and Croce CM: miRNA
clusters as therapeutic targets for hormone-resistant. Expert Rev
Endocrinol Metab. 10:607–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu DR, Guan QL, Limin X, Gao MT, Jiang L
and Kang HX: MiR-1260b is a potential prognostic biomarker in
colorectal cancer. Med Sci Monit. 22:2417–2423. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirata H, Ueno K, Nakajima K, Tabatatai
ZL, Hinoda Y, Ishii N and Dahiya R: Genistein downregulates
onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells.
Br J Cancer. 108:2070–2078. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Afonia O, Juste D, Das S, Matsuhashi S and
Samuels HH: Induction of PDCD4 tumor suppressor gene expression by
RAR agonists, antagonist in breast cancer cells. Oncogene.
23:8135–8145. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jansen AP, Camalier CE, Stark C and
Colburn NH: Characterization of programmed cell death 4 in multiple
human cancers reveals a novel enhancer of drug sensitivity. Mol
Cancer Ther. 3:103–110. 2004.PubMed/NCBI
|
|
25
|
Wei N, Liu SS, Chan KK and Ngan HY: Tumour
suppressive function and modulation of programmed cell death 4
(PDCD4) in ovarian cancer. PLoS One. 7:e303112012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin K, Liu MH, Zhang M, Wang F, Fen M, Liu
ZJ, Yuan Y, Gao S, Yang L, Zhang W, et al: miR-208a-3p suppresses
cell apoptosis by targeting PDCD4 in gastric cancer. Oncotarget.
7:67321–67332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen F, Mo M, Chen L, An S, Tan X, Fu Y,
Rezaei K, Wang Z, Zhang L and Fu SW: MicroRNA-21 down-regulates Rb1
expression by targeting PDCD4 in retinoblastoma. J Cancer.
5:804–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Foley NH, Bray IM, Tivnan A, Bryan K,
Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M and
Stallings RL: MicroRNA-184 inhibits neuroblastoma cell survival
through targeting the serine/threonine kinase AKT2. Mol Cancer.
9:832010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao N, Budhraja A, Cheng S, Liu EH, Chen
J, Yang Z, Chen D, Zhang Z and Shi X: Phenethyl isothiocyanate
exhibits antileukemic activity in vitro and in vivo by inactivation
of Akt and activation of JNK pathways. Cell Death Dis. 2:e1402011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang
E, Marincola FM, Mai C, Chen Y and Wei H: Loss of connective tissue
growth factor as an unfavorable prognosis factor activates miR-18b
by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in
nasopharyngeal carcinoma. Cell Death Dis. 4:e6342013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang WQ, Zhang H, Wang HB, Sun YG, Peng
ZH, Zhou G, Yang SM, Wang RQ and Fang DC: Programmed cell death 4
(PDCD4) enhances the sensitivity of gastric cancer cells to
TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling
pathway. Mol Diagn Ther. 14:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ivanov VN, Krasilnikov M and Ronai Z:
Regulation of Fas expression by STAT3 and c-Jun is mediated by
phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem.
277:4932–4944. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Justus CR, Leffler N, Ruiz-Echevarria M
and Yang LV: In vitro cell migration and invasion assay. J Vis Exp.
1–Jun;2014. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmitten TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2011.
View Article : Google Scholar
|
|
35
|
Liwak U, Thakor N, Jordan LE, Roy R, Lewis
SM, Pardo OE, Seckl M and Holcik M: Tumor suppressor PDCD4
repressed internal ribosome entry site-mediated translation of
antiapoptotic proteins and is regulated by S6 kinase 2. Mol Cell
Biol. 32:1818–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang S, Li J, Jiang Y, Xu Y and Oin C:
Programmed cell death 4 (Pdcd4) suppresses metastatic potential of
human hepatocellular carcinoma cells. J Exp Clin Cancer Res.
28:712009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Navarro-Quiroz E, Pacheco-Lugo L,
Navarro-Quiroz R, Lorenzi H, España-Puccini P, Díaz-Olmos Y,
Almendrales L, Olave V, Gonzalez-Torres H, Diaz-Perez A, et al:
Profiling analysis of circulating microRNA in peripheral blood of
patients with class IV lupus nephritis. PLoS One. 12:e01879732017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL and Dahiya R: Genistein down regulates
onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation
and histone modification in prostate cancer cells. Br J Cancer.
110:1645–1654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu L, Li L, Li J, Li H, Shen Q, Ping J, Ma
Z, Zhong J and Dai L: Overexpression of miR-1260b in non-samll cell
lung cancer is associated with lymph node metastasis. Aging Dis.
6:478–485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nordentoft I, Birkenkamp-Demtroder K,
Agerbak M, Thedorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft
TF and Dyrskjøt L: miRNAs associated with chemo-sensitivity in cell
lines and in advanced bladder cancer. BMC Med Genomics. 5:402012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Valeri N, Gasparini P, Braconi C, Paone A,
Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al:
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating
human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA.
107:20198–21103. 2010. View Article : Google Scholar
|
|
43
|
Zhang Z and DuBois RN: Detection of
differentially expressed genes in human colon carcinoma cells
treated with a selective COX-2 inhibitor. Oncogene. 20:4450–4456.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Palamarchuk K, Efanov A, Maximov V,
Aqeilan RI and Croce CMP: Akt phosphorylates and regulates Pdcd4
tumor suppressor protein. Cancer Res. 65:11282–11286. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bitomsky N, Bohm M and Klempnauer KH:
Transformation suppressor protein Pdcd4 interferes with
JNK-mediated phosphorylation of c-Jun and recruitment of the
coactivator p300 by c-Jun. Oncogene. 23:7484–7493. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lankat-Buttgereit B, Muller S, Schmidt H,
Parhofer KG, Gress TM and Göke R: Knockdown of Pdcd4 results in
induction of proprotein convertase 1/3 and potent secretion of
chromogranin A and secretogranin II in a neuroendocrine cell line.
Bio Cell. 100:703–715. 2008. View Article : Google Scholar
|
|
47
|
Mudduluru G, Medved F, Grobholz R, Jost C,
Gruber A, Leupold JH, Post S, Jansen A, Colburn NH and Allgayer H:
Loss of Pdcd4 expression marks adenoma-carcinoma transition,
correlates inversely with pAkt and is a new and independent
prognostic factor in resected colorectal cancer. Cancer.
110:1697–1707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Otaegi G, Yusta-Boyo MJ, Vergaño-Vera E,
Méndez-Gómez HR, Carrera AC, Abad JL, González M, de la Rosa EJ,
Vicario-Abejón C and de Pablo F: Modulation of the PI 3-kinase-Akt
signalling pathway by IGF-I and PTEN regulates the differentiation
of neural stem/precursor cells. J Cell Sci. 119:2739–2748. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cui QL and Almazan G: IGF-1 induced
oligodendrocyte progenitor proliferation requires PI3K/Akt, MEK/ERK
and Src-like tyrosine kinases. J Neurochemistry. 217:361–370.
2009.
|
